Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Here’s What Happened

Maplight Therapeutics, Inc. (NASDAQ:MPLT)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $19.64, but opened at $19.21. Maplight Therapeutics shares last traded at $20.00, with a volume of 50,988 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on MPLT shares. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective for the company. Leerink Partnrs upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a report on Friday, November 21st. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Morgan Stanley started coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price for the company. Finally, Leerink Partners started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “outperform” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Maplight Therapeutics has a consensus rating of “Buy” and a consensus price target of $31.00.

Maplight Therapeutics Price Performance

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.